Proteoglycan Splice Variants as Therapeutics and Diagnostics for Amyloid Diseases
OwnerAlan D. Snow, Qubai Hu +2inventors
InventorsAlan D. Snow, Qubai Hu, Judy A. Cam, Joel Cummings
Life of this patent
Estimating the term…
Abstract
The identification of novel Syndecan-2 splice variants and their use in the diagnosis and therapeutic intervention of Alzheimer's disease and other amyloid diseases. In addition the use of new animal models expressing or devoid of syndecan-2 splice variants to effectively screen and identify potential therapeutic compounds for Alzheimer's disease.
Claims30
An isolated polynucleotide consisting of SEQ ID NO:
- 6.
An isolated polynucleotide consisting of SEQ ID NO:
- 8.
A polynucleotide encoding a protein according to SEQ ID NO:7.
A polynucleotide encoding a protein according to SEQ ID NO:9.
A vector comprising SEQ ID NO:
- 6.
A vector comprising at least a portion of nucleotides 124-279 of SEQ ID NO:
- 6.
A vector comprising SEQ ID NO:
- 8 or a fragment thereof.
A splice variant of syndecan-2 having the sequence of SEQ ID NO:
- 7.
A splice variant of syndecan-2 having the sequence of SEQ ID NO:
- 9 or a fragment thereof.
A polypeptide comprising at least a portion of amino acids 21-72 of SEQ ID NO:
- 7.
A polypeptide as set forth in SEQ ID NO:9 or a fragment thereof.
A method for detection and/or quantitation of a splice variant of syndecan-2 in a biological sample, the method comprising;
- synthesizing cDNA from mRNA in the sample, amplifying portions of the cDNA corresponding to the splice variant or fragments thereof and detecting/quantitating the amplified cDNA.
An antibody that binds to an epitope comprising at least several of amino acids 21-72 of SEQ ID NO:
- 7.
Dependencies are inferred from the claim text.